A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment
Crossref DOI link: https://doi.org/10.1007/s11239-016-1386-8
Published Online: 2016-06-25
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Woodruff, Seth
Feugère, Guillaume
Abreu, Paula
Heissler, Joseph
Ruiz, Marcia T.
Jen, Frank
Funding for this research was provided by:
Pfizer (None)
License valid from 2016-06-25